SAN DIEGO, Dec. 08, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results